Article thumbnail

Effectiveness of Erythropoietin in Hypertensive Hemodialysis Patients

By Susannia Ibrahim, Ajeng Diantini, Budhi Prihartanto and Rudi Supriyadi

Abstract

Chronic renal failure (CRF) is one the most prevalent health problems among the elderly. On the fifth stage of CRF, the patient becomes eligible to hemodialysis. CRF-induced anemia is commonly treated with Erythropoietin (Epo). Information regarding the effectiveness of Epo in hypertensive hemodialysis patients was limited. Therefore, this study was conducted to evaluate the effectiveness of Epo in hypertensive hemodialysis patients. This study used an observational case-control analytic method. Data were retrieved from the medical records of hemodialysis patients during March-May 2014. A total of 54 participants were included. The increase of haemoglobin (Hb) in controlled hypertension was 0.6257 g/dl, while the in uncontrolled hypertension group, there was a decrease in Hb (-0.1590 g/dl). The use of Epo was more effective in hemodialysis patients with controlled hypertension. Keywords: chronic kidney disease, erythropoietin, hypertensio

Topics: Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441
Publisher: Universitas Padjadjaran
Year: 2018
OAI identifier: oai:doaj.org/article:5c352ddfa12e47bfbfbc342a509607ec
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2527-7332 (external link)
  • http://jurnal.unpad.ac.id/pcpr... (external link)
  • https://doaj.org/article/5c352... (external link)
  • https://doaj.org/toc/2614-0020 (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.